COVID-19 vaccine may still be ready by end of year despite suspected spinal problem that halted trial, AstraZeneca CEO says

Alan Condon -   Print  |

AstraZeneca on Sept. 8 shut down its clinical trial evaluating a potential vaccine for COVID-19, but CEO Pascal Soriot said the vaccine could still be available by the end of the year, Business Insider reports.

The biopharmaceutical company paused the global clinical trial after a participant in the United Kingdom suffered an adverse reaction.

The New York Times reported the illness as transverse myelitis, an inflammation of the spinal cord that interrupts messages that nerves send throughout the body.

AstraZeneca has initiated a safety review and has not given a timeline for when the trial may resume. 

More articles on spine:
The evolution of MIS SI joint: 6 key developments since CMS upped rates 27%
Losing its orthopedic provider to a competitor, New York system taps new partner
Orthopedic rankings, robotics & more: 6 key developments at Mayo Clinic during the pandemic

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers